ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications   Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug discovery innovation centre, have signed a non-exclusive commercial-use CRISPR license agreement. The partnership combines ERS’s CRISPR/Cas9 patent portfolio with MDC’s world-class expertise and technology. MDC and its partners will benefit from access to ERS’ entire CRISPR/Cas9 portfolio – the foundational CRISPR/Cas9 intellectual property held by